Poster Abstracts

Posters

A good example of two VERTICAL posters hanging side by side. Dimensions should be no taller than 4′ and no wider than 3′.

  • The Poster viewing session will be held on Thursday, October 18th from 3:30 to 5:00 pm
  • Resident posters must be hung by Thursday, October 18th at 3 pm.  All posters must be removed by 3:30 pm on Saturday, October 20th.
  • At 3:00 pm, all RESIDENT poster presenters will provide a less than 2 minute ORAL synopsis of their poster in the main ballroom.  One slide will be accepted to go along with this brief oral presentation and instructions on how to prepare that slide will be sent to all residents in competion approximately one month prior to the conference.
  • All residents must stand with their posters until judging is complete (approximately 5 pm).
  • For questions regarding poster size, see photo above and scroll towards the bottom of the ABSTRACT PAGE.

PresenterAbstract Title
Dr. Blake MarcumBiodynamic imaging of bone marrow aspirates from tumor-bearing dogs as a predictor
of chemotherapy-induced neutropenia: A pilot study
Dr. Emily KriegerCanine primary, multicentric, and metastatic intraocular neoplasia: A retrospective study
Dr. Elizabeth MorganCanine T Cell Lymphoma treated with Lomustine, Vincristine, Procarbazine
and Prednisolone (LOPP) chemotherapy in 35 dogs
Dr. Annie GallowayCHOP dose escalation for canine lymphoma
Dr. Hiroki YamazakiClinical and biological evaluation of postoperative adjuvant therapy using
toceranib phosphate against adenocarcinoma in dogs
Ms. Jocelyn BissonEvaluation of a 0.75 x 10^9/l absolute neutrophil count cut-off for antimicrobial
prophylaxis in veterinary cancer chemotherapy patients
Dr. Yusuke MuraseGedatolisib (PF-05212384), a dual PI3K/mTOR inhibitor, induces anti-tumor
activity and P-glycoprotein is involved in the resistance in canine tumors in vitro
Dr. Brittanie PartridgeHigh frequency irreversible electroporation for the treatment of primary
liver cancer: A pilot study
Dr. Kei HaradaIs toceranib phosphate-induced neutropenia an efficacy biomarker in dogs
with malignant tumors?
Dr. Katrina ChengLymphoma in Australian Border Collies (ABC): Survey and pedigree analysis
Dr. Tatsuya DeguchiMetformin radiosensitizes cancer stem-like cells but not non-stem cells in
canine osteosarcoma cell line by AMPK/mTOR-independent mechanism
Dr. Keijiro ShiomitsuMolecular diagnosis using RNA-scope in situ hybridization in canine malignancies
Dr. Tomoko TakahashiOutcomes of dogs with nasal epithelial tumors treated with or without radiation therapy
Dr. Sho YoshimotoOverexpression of HER2 in canine anal sac adenocarcinoma
Dr. Matthew DowlingOverexpression of prostate specific membrane antigen by canine
hemangiosarcoma cells allows of microscopic disease detection in blood
with polymerase chain reaction
Dr. Gabrielle CarterPrognosis and prognostic indicators for canine patients with primary intracranial
neoplasia treated with CyberKnife radiotherapy
Dr. Brittany WittenbernsSplenic stromal sarcoma in 47 dogs: A retrospective analysis
Dr. Stacy Fox-AlvarezStereotactic radiation therapy for treatment of canine nasal carcinomas